Cellenkos
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5416 Chaucer Dr, Houston, Texas, 77005, ...Phone Number
(800) 217-8247Website
www.cellenkosinc.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cellenkos
Cellenkos is a clinical-stage biotech company focused on the development and commercialization of transformative novel allogeneic Treg cell therapies to treat autoimmune and inflammatory disorders. Cellenkos was founded in 2016 and is located in Texas, the United States.Explore more
Cellenkos Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellenkos your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Cellenkos launches new products
Congratulate Masked Content for being promoted to Masked Content at Cellenkos
Website visits: Recent activity has been detected on your website
Cellenkos, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Cellenkos has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Cellenkos has new funding data
Check out if Cellenkos is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Cellenkos had a recent Job posting/layoffs
Earning: See what the market has to say on Cellenkos recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Cellenkos as Masked Content
Find 3 more new buyers
Compare Similar Companies to Cellenkos
Compare insights from companies similar to Cellenkos, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cellenkos is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cellenkos is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cellenkos.
Cellenkos financials insights
Gather financial insights about Cellenkos, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Cellenkos Tech Stack
A closer look at the technologies used by Cellenkos
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Safety, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Compliance, Legal Affairs, Pharmaceuticals, Healthcare Technology, Regulations
Event
Person-Based
Events, Search, Medical Research
Cellenkos News & Media
Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia
Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia. HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic,...FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis
-- CK0804 is a first in class, CXCR4hi Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over expressed in the bone marrow and spleen in myelofibrosis. -- CK0804 engages with antigen presenting cells within target tissues and undergoes in vivo proliferation to...Dose-Intensive CK0804 Regimen Reduces Spleen Volume and Transfusion Needs in JAK Inhibitor-Resistant/ Suboptimal Myelofibrosis with Thrombocytopenia
Dose-intensive CK0804 Treg regimen appears to overcome JAK inhibitor treatment resistance Durable spleen volume reduction and decreased transfusion burden are associated with reduced inflammatory biomarkers following CK0804 Treg therapy Cellenkos will initiate phase 2 trial of CK0804 in...FDA Grants Orphan Drug Designation to Cellenkos' CK0803 Tregs for Treatment of Amyotrophic Lateral Sclerosis
Orphan Drug Designation granted to CK0803 for Amyotrophic Lateral Sclerosis CK0803 is CNS Homing Tregs expressing CXCR3hi, CXCR7+, LFA1+ CK0803 is planned for Randomized Placebo Control Trial in 2026 HOUSTON, Oct. 20, 2025 /PRNewswire/ -- Cellenkos® Inc., a clinical-stage biotechnology...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellenkos
Sign Up For FreeTo access detailed company insights
Cellenkos is a clinical-stage biotech company focused on the development and commercialization of transformative novel allogeneic Treg cell therapies to treat autoimmune and inflammatory disorders. Cellenkos was founded in 2016 and is located in Texas, the United States.... Read More
